Literature DB >> 21493867

The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas.

Björn Koos1, Sebastian Bender, Hendrik Witt, Sonja Mertsch, Jörg Felsberg, Rudi Beschorner, Andrey Korshunov, Barbara Riesmeier, Stefan Pfister, Werner Paulus, Martin Hasselblatt.   

Abstract

PURPOSE: Ependymomas are glial tumors of presumably radial glial origin that share morphologic similarities with ependymal cells. The molecular genetics of ependymomas of supratentorial, infratentorial, and spinal location is heterogeneous. We aimed at identifying pathways operative in the development of infratentorial ependymomas. EXPERIMENTAL
DESIGN: To do so, gene expression profiles of tumor cells laser microdissected from infratentorial ependymomas (n = 15) were compared with that of nonneoplastic ependymal cells laser microdissected from autopsy tissue (n = 7).
RESULTS: Among 31 genes significantly overexpressed (>5-fold) in ependymomas, transcription factor EVI1 (ecotropic viral integration site 1) showed the highest overexpression (35-fold). Evi-1 protein expression could be confirmed in formalin-fixed, paraffin-embedded samples of 26 of 28 infratentorial ependymomas but only in 7 of 47 nonependymal glial tumors (P < 0.001). Furthermore, MDS1/EVI1 fusion transcripts were detectable in 17 of 28 infratentorial ependymomas and significantly correlated with MGMT (O6-methylguanine-DNA-methyltransferase) promoter hypermethylation (P < 0.05). In primary infratentorial ependymoma cells, transfection with EVI1-specific siRNAs resulted in significant growth inhibition [48 hours: 87% ± 2% and 74% ± 10% as compared with control (mean ± SD; P < 0.001)]. The prognostic role of EVI1 could further be validated in an independent cohort of 39 infratentorial and 26 supratentorial ependymomas on the basis of mRNA expression profiling. Although in supratentorial ependymomas EVI1 expression status had no prognostic impact, in infratentorial ependymomas, high EVI1 expression was associated with shorter overall survival and progression-free survival.
CONCLUSIONS: To conclude, the transcription factor Evi-1 is overexpressed in infratentorial ependymomas, promotes proliferation of ependymal tumor cells, and is prognostically unfavorable. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21493867     DOI: 10.1158/1078-0432.CCR-11-0175

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.

Authors:  Xiyun Deng; Yanna Cao; Yan Liu; Fazhi Li; Kamalanathan Sambandam; Srinivasan Rajaraman; Archibald S Perkins; Alan P Fields; Mark R Hellmich; Courtney M Townsend; E Aubrey Thompson; Tien C Ko
Journal:  Mol Carcinog       Date:  2011-12-07       Impact factor: 4.784

2.  Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors.

Authors:  Emilie A Bard-Chapeau; Justin Jeyakani; Chung H Kok; Julius Muller; Belinda Q Chua; Jayantha Gunaratne; Arsen Batagov; Piroon Jenjaroenpun; Vladimir A Kuznetsov; Chia-Lin Wei; Richard J D'Andrea; Guillaume Bourque; Nancy A Jenkins; Neal G Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-19       Impact factor: 11.205

3.  Ependymoma stem cells are highly sensitive to temozolomide in vitro and in orthotopic models.

Authors:  Daniela Meco; Tiziana Servidei; Giuseppe Lamorte; Elena Binda; Vincenzo Arena; Riccardo Riccardi
Journal:  Neuro Oncol       Date:  2014-02-12       Impact factor: 12.300

Review 4.  Spinal cord ependymomas in children and adolescents.

Authors:  Martin Benesch; Didier Frappaz; Maura Massimino
Journal:  Childs Nerv Syst       Date:  2012-09-08       Impact factor: 1.475

5.  Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.

Authors:  Carolyn Glass; Charles Wuertzer; Xiaohui Cui; Yingtao Bi; Ramana Davuluri; Ying-Yi Xiao; Michael Wilson; Kristina Owens; Yi Zhang; Archibald Perkins
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

6.  Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival.

Authors:  Amanda E Marinoff; Clement Ma; Dongjing Guo; Matija Snuderl; Karen D Wright; Peter E Manley; Hasan Al-Sayegh; Claire E Sinai; Nicole J Ullrich; Karen Marcus; Daphne Haas-Kogan; Liliana Goumnerova; Wendy B London; Mark W Kieran; Susan N Chi; Jason Fangusaro; Pratiti Bandopadhayay
Journal:  J Neurooncol       Date:  2017-07-21       Impact factor: 4.130

7.  miR-1 inhibits the proliferation of breast cancer stem cells by targeting EVI-1.

Authors:  Lei Wu; Tianyi Wang; Dongning He; Xiaoxi Li; Youhong Jiang
Journal:  Onco Targets Ther       Date:  2018-12-06       Impact factor: 4.147

8.  Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.

Authors:  Emilie A Bard-Chapeau; Dorota Szumska; Bindya Jacob; Belinda Q L Chua; Gouri C Chatterjee; Yi Zhang; Jerrold M Ward; Fatma Urun; Emi Kinameri; Stéphane D Vincent; Sayadi Ahmed; Shoumo Bhattacharya; Motomi Osato; Archibald S Perkins; Adrian W Moore; Nancy A Jenkins; Neal G Copeland
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

9.  EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.

Authors:  Roberto Paredes; Marion Schneider; Adam Stevens; Daniel J White; Andrew J K Williamson; Joanne Muter; Stella Pearson; James R Kelly; Kathleen Connors; Daniel H Wiseman; John A Chadwick; Harald Löffler; Hsiang Ying Teng; Simon Lovell; Richard Unwin; Henri J van de Vrugt; Helen Smith; Olga Kustikova; Axel Schambach; Tim C P Somervaille; Andrew Pierce; Anthony D Whetton; Stefan Meyer
Journal:  Nucleic Acids Res       Date:  2018-09-06       Impact factor: 16.971

10.  EVI‑1 acts as an oncogene and positively regulates calreticulin in breast cancer.

Authors:  Lei Wu; Tianyi Wang; Dongning He; Xiaoxi Li; Youhong Jiang
Journal:  Mol Med Rep       Date:  2018-12-24       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.